RT Conference Proceedings
T1 Study of the combination gemcitabine and trastuzumab in the treatment of HER2+ metastatic breast cancer
A1 Menjón-Beltrán, S
A1 Olivencia-Dueso, R
A1 González-Jiménez, E
A1 Titos, MJ
K1 Anticuerpos Monoclonales Humanizados
K1 Antineoplásicos
K1 Neoplasias de la Mama
K1 Metástasis de la Neoplasia
K1 Antimetabolitos Antineoplásicos
K1 Femenino
K1 Humanos
K1 Receptor erbB-2
AB Trastuzumab and gemcitabine are two active drugs for meta-static breast cancer (MBC) treatment. We conducted a retrospective study of this combination in patients with Her2+ MBC in our hospital.
PB BioMed Central
SN 1465-5411
YR 2007
FD 2007-06-19
LK http://hdl.handle.net/10668/556
UL http://hdl.handle.net/10668/556
LA en
NO Menjón-Beltrán S, Olivencia-Dueso R, González-Jiménez E, Titos MJ .Study of the combination gemcitabine and trastuzumab in the treatment of HER2+ metastatic breast cancer. Breast Cancer Research 2007, 9(Suppl 1):P11
NO Poster Presentation. This article is part of the supplement: VII Madrid Breast Cancer Conference: Changes in the treatment of breast cancer.
DS RISalud
RD Apr 16, 2025